Market Snapshot: Migraine Prevention Therapies’ Slow Road To Blockbuster Status
Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.
You may also be interested in...
Teva's turnaround is progressing, but the company forecast largely flat revenues and earnings in 2020. A threat to the improved stability is how an opioid litigation settlement might unfold.
Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.
The Danish drugmaker's four 'strategic brands' – Brintellix, Abilify Maintena, Northera and Rexulti – are selling well. Now the focus is firmly on breaking into the anti-CGRP market with eptinezumab.